Faculty Opinions recommendation of Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

2016 ◽  
Author(s):  
Scott Kaufmann ◽  
Wei Meng
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

2016 ◽  
Vol 17 (6) ◽  
pp. 768-778 ◽  
Author(s):  
Stephan Stilgenbauer ◽  
Barbara Eichhorst ◽  
Johannes Schetelig ◽  
Steven Coutre ◽  
John F Seymour ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

2018 ◽  
Vol 5 (4) ◽  
pp. e170-e180 ◽  
Author(s):  
Jennifer R Brown ◽  
Mehdi Hamadani ◽  
John Hayslip ◽  
Ann Janssens ◽  
Nina Wagner-Johnston ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Hodgkin Lymphoma ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Open Label Phase

scholarly journals Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study

2016 ◽  
Vol 3 (1) ◽  
pp. e22-e29 ◽  
Author(s):  
Bogdan Dumitriu ◽  
Sawa Ito ◽  
Xingmin Feng ◽  
Nicole Stephens ◽  
Muharrem Yunce ◽  
...  
Keyword(s):  
T Cell ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

2018 ◽  
Vol 19 (1) ◽  
pp. 65-75 ◽  
Author(s):  
Jeffrey A Jones ◽  
Anthony R Mato ◽  
William G Wierda ◽  
Matthew S Davids ◽  
Michael Choi ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Interim Analysis ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document